Your SlideShare is downloading. ×
0
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
14 rencontres biomédicale LIR Philippe Menasché
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

14 rencontres biomédicale LIR Philippe Menasché

591

Published on

2ND INTERNATIONAL RESEARCH MEETING …

2ND INTERNATIONAL RESEARCH MEETING
4 JUNE 2010- HÔTEL DE MARIGNY PARIS

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
591
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Stem Cells: Therapeutic Approaches and Pharmaceutical Screening in Cardiovascular Diseases Ph.Menasché Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou & INSERM U633, Paris
  • 2. Stem Cells in France: Research and Therapy <ul><li>Strengths </li></ul><ul><li>- Long-standing experience in cell therapy </li></ul><ul><li>- Current efforts to streamline the regulatory process for implementing clinical trials </li></ul><ul><li>- Tight interactions between basic science laboratories and clinical departments facilitating translational research </li></ul>
  • 3. Embryonic Stem Cells in France <ul><li>The Specific Regulatory Environment of ESC </li></ul><ul><li>- Permission to work on human ESC under specific approval by a dedicated Agency </li></ul><ul><li>- To date, 31 approved research teams totalling </li></ul><ul><li>39 imported and 24 on-site derived hESC lines </li></ul><ul><li>- Pending reassessment of the Bioethical Law with low probability of a backward shift </li></ul>
  • 4. Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective : Myocardial regeneration </li></ul><ul><li>- Preclinical studies of skeletal myoblasts in rodents and sheep (1995-2000) </li></ul>Engraftment of myoblasts in an infarcted sheep heart
  • 5. Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective : Myocardial regeneration </li></ul><ul><li>- Clinical trials (myoblast Tx + CABG) : </li></ul><ul><li>First in-man Phase I (2000-2001) : 10 patients </li></ul><ul><li>Phase II (2002-2006) : 97 patients </li></ul>MG Biotherapeutics Multicentric Randomized Controlled Dose ranging Double blind Myoblast Autologous Grafting in Ischemic Cardiomyopathy Myoblast injections in infarcted myocardium
  • 6. Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective : Myocardial regeneration </li></ul><ul><li>- Shift towards human ESC-derived cardiac progenitors (2005- ongoing) </li></ul><ul><li>Preclinical studies in rodents and nonhuman primates </li></ul><ul><li>Translational studies in preparation for a pilot phase I trial (scale-up under GMP conditions, extensive safety testing, validation of preclinical runs, development of a cell-seeded biomaterial) </li></ul>Blin et al. J Clin Invest 2010; 120:1125-39.
  • 7. Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells should be tailored to the primary clinical indication </li></ul><ul><li>- Upgrading cells to a « product » may require allogeneic tissue sources </li></ul><ul><li>- Cell engraftment (retention + survival) rates must be optimized </li></ul>
  • 8. Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells should be tailored to the primary clinical indication </li></ul><ul><li>- Upgrading cells to a « product » may require allogeneic tissue sources </li></ul><ul><li>- Cell engraftment (retention + survival) rates must be optimized </li></ul>
  • 9. Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells should be tailored to the primary clinical indication </li></ul><ul><li>- Upgrading cells to a « product » may require allogeneic tissue sources </li></ul><ul><li>- Cell engraftment (retention + survival) rates must be optimized </li></ul>
  • 10. Induced Pluripotent Stem Cells Yamanaka S Cell 2009;137:13-17.
  • 11. Induced Pluripotent Stem Cells Cell Stem Cell 2010;6:407-11. <ul><li>Assets of France </li></ul><ul><li>Development of iPS technology based on </li></ul><ul><li>previous ESC experience </li></ul><ul><li>Large patient cohorts </li></ul><ul><li>Planning to launch government-funded </li></ul><ul><li>Technology Research Institutes in partnership </li></ul><ul><li>with private biotech/pharma companies </li></ul>

×